Despite
the wide use of magnetic resonance imaging (MRI) as a clinical
diagnostic tool, there are still no clinically approved MRI contrast
agents that can be applied for cerebral Alzheimer’s disease
(AD) biomarker imaging. We report here the design and development
of the first amyloid-β (Aβ)-targeted, blood–brain
barrier (BBB) penetrable theranostic Gd(DOTA)-cyanine dyad, which
was synthesized by the conjugation of Gd(DOTA) complex and carbazole-based
cyanine dye by the copper(I)-catalyzed azide-alkyne cycloaddition
click reaction for imaging of Aβ in vivo and ex vivo in AD mouse models. This dyad, as a multimodal probe,
possesses desirable multifunctional properties, including good biocompatibility,
low cytotoxicity, high Aβ selectivity, strong fluorescence enhancement
upon binding with Aβ species, good paramagnetic properties,
high stability, good BBB penetrability, and fast elimination from
the mouse. The longitudinal relaxivity (r
1) of the dyad was found to be 4.42 mM–1 s–1 at 3 T, suggesting it to be promising as a T
1-weighted MRI contrast agent. The probe has been successfully
demonstrated to be able to be applied for one- and two-photon excited
fluorescence and magnetic resonance (MR) imaging of Aβ in transgenic
mouse models of AD. In addition, it can inhibit Aβ aggregation,
protect against toxicity induced by Aβ, and suppress Aβ-induced
reactive oxygen species (ROS) production. Our results demonstrate
the highly promising theranostic capability of the dyad for diagnosis
and therapy of AD and extraordinary potential for MRI of Aβ
in humans.